Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), comprising the complete 44-amino-acid GHRH(1-44) sequence with a trans-3-hexenoic acid group attached at the N-terminus. It is studied as a stimulator of endogenous, pulsatile growth hormone release from the anterior pituitary, acting through the GHRH receptor, and it is distinguished within the GHRH analogue class by both its full-length native sequence and its resistance to rapid enzymatic degradation. This article reviews tesamorelin’s structure, receptor mechanism, key published studies, research applications and the handling requirements relevant to a laboratory setting.
What is tesamorelin?
Tesamorelin is built from the full 44-residue sequence of human GHRH, with a trans-3-hexenoic acid moiety conjugated to the alpha-amino group of the N-terminal tyrosine residue; it carries the full name trans-3-hexenoyl-hGHRH(1-44)-NH2. Its molecular weight is approximately 5,136 g/mol, and it is assigned CAS registry number 218949-48-5. Unlike many GHRH-related research peptides, which are truncated fragments, tesamorelin retains the complete native sequence, meaning its receptor-binding region is structurally identical to endogenous GHRH; the only modification is the N-terminal hexenoyl group.
That modification serves a specific purpose: native GHRH has a short circulating half-life because the enzyme dipeptidyl peptidase IV (DPP-4) rapidly cleaves its N-terminal dipeptide. The trans-3-hexenoyl group sterically blocks this cleavage site, substantially extending tesamorelin’s plasma stability relative to unmodified GHRH while leaving its receptor-binding domain unaltered. Tesamorelin was developed by Theratechnologies as part of a research programme into stabilised GHRH analogues and was subsequently characterised in a series of published clinical pharmacology studies, described below, that examined its effects on growth hormone secretion and downstream metabolic parameters in defined patient populations.
Mechanism of action
Tesamorelin acts on the GHRH receptor (GHRH-R), a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Because tesamorelin’s receptor-binding domain is identical to that of native GHRH, receptor engagement and downstream signalling proceed through the same pathway: coupling to Gs proteins, activation of adenylyl cyclase, and a resulting rise in intracellular cyclic AMP, which activates protein kinase A and drives synthesis and exocytotic release of growth hormone from somatotroph secretory granules.
Because tesamorelin stimulates the pituitary’s own growth hormone secretory machinery rather than supplying growth hormone directly, it is reported in the published literature to preserve the physiological pulsatile pattern of growth hormone release, in contrast to exogenous growth hormone administration, which produces sustained, non-pulsatile elevation. This distinction is reported to matter for downstream signalling, since pulsatile versus continuous growth hormone exposure can differentially affect gene expression in target tissues, a general principle established in growth hormone physiology research more broadly rather than one specific to tesamorelin.
Growth hormone released in response to GHRH-R activation acts at peripheral tissues both directly and, substantially, through stimulating hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), which mediates much of growth hormone’s downstream metabolic signalling. Published pharmacology studies describe tesamorelin’s extended plasma stability, arising from DPP-4 resistance, as the structural basis for its ability to sustain elevated GHRH receptor engagement across a dosing interval relative to native, rapidly degraded GHRH, without altering the fundamental receptor pharmacology involved.
What the research shows
The foundational characterisation of tesamorelin’s effects was reported by Falutz and colleagues in a multicentre, randomised, placebo-controlled Phase 3 trial published in the New England Journal of Medicine in 2007. The study examined tesamorelin administration over 26 weeks in a defined patient population with abdominal fat accumulation, with visceral adipose tissue, measured by computed tomography, as the primary endpoint. The investigators reported that tesamorelin produced a significant reduction in visceral adipose tissue relative to placebo, along with improvements in triglyceride and cholesterol measures, without a significant worsening of overall glucose tolerance in the study population (Falutz et al., 2007, PubMed).
A separate randomised, double-blind, placebo-controlled trial, reported by Stanley and colleagues in JAMA in 2014, examined both visceral and liver fat as co-primary endpoints over a six-month treatment period in a smaller cohort. The study reported that tesamorelin significantly reduced visceral adipose tissue, measured by computed tomography, and also produced a measurable reduction in liver fat content, assessed by magnetic resonance spectroscopy, with the reduction in liver fat found to correlate significantly with the reduction in visceral fat across the study population (Stanley et al., 2014, PubMed).
A more recent secondary analysis, reported by Erlandson and colleagues in 2019, examined skeletal muscle outcomes using existing trial imaging data, reporting that tesamorelin treatment was associated with decreased muscle fat content and increased muscle cross-sectional area relative to placebo in the study population, extending the characterisation of tesamorelin’s metabolic effects beyond visceral and liver adiposity to skeletal muscle composition (Erlandson et al., 2019, PMC).
A substantial additional body of published clinical pharmacology work, including long-term safety extension studies and pooled analyses of the original Phase 3 trials, has further characterised tesamorelin’s effects on inflammatory markers, liver enzymes and metabolic profile in the same general patient population studied in the foundational trials. Because this literature is extensive and consists predominantly of further analyses drawing on the same core trial programme, readers wanting additional primary detail should consult a review of the tesamorelin clinical trial literature rather than a single summarised study here.
Research applications
In the laboratory, tesamorelin is used chiefly as a pharmacological tool for studying GHRH receptor signalling and its downstream effects on the growth hormone/IGF-1 axis, drawing on its full-length native receptor-binding sequence as a reference ligand structurally equivalent to endogenous GHRH. Because of its extended stability relative to native GHRH, it is also used in studies requiring sustained GHRH receptor engagement over longer experimental timeframes than unmodified GHRH would allow.
Cell-based pituitary and GHRH-R-expressing cell line models are used to characterise receptor binding, cyclic AMP accumulation and growth hormone secretory responses to tesamorelin, often in comparison with native GHRH and with other stabilised GHRH analogues developed for similar research purposes. Because of the extensive clinical pharmacology literature summarised above, tesamorelin is also used as a reference compound in research examining the relationship between growth hormone secretion patterns, visceral adiposity, liver fat and skeletal muscle composition, areas where its well-characterised effects on these specific outcome measures make it a useful comparator for newer growth hormone secretagogues under development.
Purity, storage and handling
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Tesamorelin should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and those comparing suppliers should look for the same documentation from any best peptides supplier UK they consider.
Reversed-phase HPLC separates the intact 44-residue peptide from truncated or deletion sequences and residual synthesis by-products, and research-grade material is commonly specified at 98% purity or above. Mass spectrometry alongside HPLC confirms identity against the expected mass of approximately 5,136 daltons for the free peptide, with the observed mass differing where the material is supplied as an acetate salt. Given the peptide’s relatively large size for a synthetic research peptide, confirming full-length integrity rather than partial degradation products is particularly relevant to reproducible receptor-binding data. A batch-specific certificate of analysis, rather than a generic product datasheet, is what links a physical vial to those results and allows unexpected experimental data to be traced back to a defined lot.
Lyophilised tesamorelin should be kept sealed at -20°C for long-term storage, protected from moisture and light, and brought to room temperature before opening so that condensation does not enter the vial. Once reconstituted in sterile water or an appropriate buffer, the peptide should be divided into single-use aliquots, held at 2–8°C only for short working periods, and otherwise kept frozen, since repeated freeze–thaw cycles risk degrading the peptide. The tyrosine and tryptophan residues within the 44-residue sequence are susceptible to photo-oxidation, so amber vials or foil-wrapped storage are sensible precautions during handling. Published reconstituted-stability data are available in the pharmaceutical formulation literature given tesamorelin’s clinical use, but laboratories working with research-grade material should still validate their own working window empirically, for example by comparing HPLC profiles of fresh and aged aliquots.
Frequently asked questions
What is tesamorelin used for in research?
It is used mainly as a pharmacological tool for studying GHRH receptor signalling and the growth hormone/IGF-1 axis, and as a reference compound in research examining the relationship between growth hormone secretion, visceral adiposity, liver fat and skeletal muscle composition. It is not evaluated here as a treatment, and this article makes no claims about use in humans.
How does tesamorelin differ from native GHRH?
Tesamorelin contains the identical 44-amino-acid GHRH(1-44) sequence, with the only structural difference being a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue. This modification blocks cleavage by the enzyme DPP-4, substantially extending tesamorelin’s plasma stability relative to native GHRH without altering its GHRH receptor-binding region.
What have published studies found about tesamorelin?
Published randomised, placebo-controlled trials have reported that tesamorelin administration is associated with reductions in visceral adipose tissue and liver fat, alongside favourable changes in triglyceride levels, in defined clinical trial populations, with a further analysis reporting reduced muscle fat content and increased muscle area. These are published clinical trial findings in named study populations, not general guidance applicable to any individual.
Is tesamorelin an approved medicine?
Tesamorelin is a licensed prescription medicine in several countries, marketed under the name Egrifta, for a specific indication in a defined patient population under specialist clinical supervision. This article concerns laboratory research material only, which is not equivalent to a licensed pharmaceutical product, and makes no claims about administration to humans or animals.
The tesamorelin discussed in this article is supplied for in-vitro and in-vivo laboratory research only. It is not intended for human or veterinary use, and nothing in this article should be read as guidance on administration to people or animals.
